AVALO THERAPEUTICS, INC. (AVTX) Gross margin 2016–2023
AVALO THERAPEUTICS, INC. (AVTX) gross margin by fiscal year — reported gross profit divided by reported revenue.
33.3%FY2023 · since FY2016: 100.0% → 33.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | 33.3% | -47.7 pp |
| FY2022 | 81.0% | +8.6 pp |
| FY2021 | 72.4% | -23.1 pp |
| FY2020 | 95.5% | -12.9 pp |
| FY2019 | 108.4% | +54.8 pp |
| FY2018 | 53.6% | -44.1 pp |
| FY2017 | 97.7% | -2.3 pp |
| FY2016 | 100.0% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice